title: Human Tumor Antigens and Cancer Immunotherapy.
abstract: With the recent developments of adoptive T cell therapies and the use of new monoclonal antibodies against the immune checkpoints, immunotherapy is at a turning point. Key players for the success of these therapies are the cytolytic T lymphocytes, which are a subset of T cells able to recognize and kill tumor cells. Here, I review the nature of the antigenic peptides recognized by these T cells and the processes involved in their presentation. I discuss the importance of understanding how each antigenic peptide is processed in the context of immunotherapy and vaccine delivery.
authors.affiliation: Ludwig Institute for Cancer Research, 1200 Brussels, Belgium ; WELBIO (Walloon Excellence in Life Sciences and Biotechnology), 1200 Brussels, Belgium ; de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Vigneron
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines